Skip to content

Serotonin Reuptake Inhibition Reduces NMDAR-Associated Reward Liability Without Compromising Rapid Antidepressant Efficacy

Libiao Pan, Guan Wang, Jing Ji, Yuting Cai, Yingting Pang, Yanmei Chen, Qiaohui Lu, Xuhua Tang, Zhengtao Hu, Baiyang Zheng, Yangyang Xiang, Qiongqiong Hou, Ke Nie, Jiangyu Zhao, Tianwen Hu, Yang He, Yan Zhang, Vivien Shen, Weiliang Zhu, Haji Akber Aisa, Guanghui Tian, Jingshan Shen

bioRxiv (Cold Spring Harbor Laboratory) November 9, 2026 preprint DOI: 10.64898/2026.11.01.763059 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical study
Population Chronic stress models of depression (preclinical)
Interventions S-ketamine escitalopram VV147
Topics Serotonin
Key points The authors report that escitalopram attenuates S-ketamine-induced dopamine release in the nucleus accumbens, and that a newly designed compound, VV147, which combines SERT inhibition with NMDAR antagonism, did not increase nucleus accumbens dopamine signaling while retaining rapid antidepressant effects in chronic stress models. They suggest a potential dissociation between rapid antidepressant efficacy and acute dopamine activation.

Abstract

Ketamine has changed the treatment landscape for depression by providing rapid antidepressant effects, yet its clinical utility remains limited by psychotomimetic effects and abuse potential. It remains unclear whether rapid antidepressant efficacy can be dissociated from mesolimbic dopamine activation and its associated reward-related effects. Here, we show that the serotonin reuptake inhibitor escitalopram, by enhancing serotonergic signaling, attenuates S-ketamine-induced dopamine (DA) release in the nucleus accumbens (NAc). Inspired by this finding, we designed and evaluated VV147 by incorporating SERT inhibition into NMDAR antagonism to reduce the reward-related liability of NMDAR blockade. Unlike S-ketamine, VV147 did not increase NAc dopamine signaling but retained rapid antidepressant effects in chronic stress models of depression. Together, these findings suggest a potential dissociation between rapid antidepressant efficacy and acute dopamine activation, providing a possible strategy for developing rapid-acting antidepressants with reduced dopamine-related reward effects.

Comparable studies

Other preclinical and animal studies on serotonin, most cited first.

Citations in the library

Explore topics